S&P TSX Capped Composite...

US Dollar vs CAD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

JNJ Johnson and Johnson

160.05

3.77 (2.41%)

Jul 25 2024 - Closed

Delayed by 15 minutes

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Jun 2024 to Jul 2024

Click Here for more Johnson and Johnson Charts.

Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Jul 2023 to Jul 2024

Click Here for more Johnson and Johnson Charts.

Johnson and Johnson News

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Thursday 25 July 2024 (10 hours ago) • Edgar (US Regulatory)

Johnson & Johnson to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Tuesday 23 July 2024 (2 days ago) • Business Wire

Lawyers for Ovarian Cancer Victims Urge NO Vote on J&J’s Latest Bankruptcy Plan
Monday 22 July 2024 (4 days ago) • Business Wire

Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with treatment-resistant depression
Monday 22 July 2024 (4 days ago) • PR Newswire (US)

Form 8-K - Current report
Wednesday 17 July 2024 (1 week ago) • Edgar (US Regulatory)

Tech-Led Decline in U.S. Index Futures Pre-Market, Oil Prices Steady After U.S. Inventory Drop
Wednesday 17 July 2024 (1 week ago) • IH Market News

Spirit Airlines Cuts Revenue Forecast, J.B. Hunt Disappoints Analysts’ Estimates, and More Earnings Updates
Wednesday 17 July 2024 (1 week ago) • IH Market News

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2024
Wednesday 17 July 2024 (1 week ago) • Business Wire

Johnson & Johnson reports Q2 2024 results
Wednesday 17 July 2024 (1 week ago) • Business Wire

Johnson & Johnson Strengthens Pipeline to Lead in Atopic Dermatitis With the Completion of the Acquisition of Yellow Jersey Therapeutics, Gaining Ownership of NM26
Thursday 11 July 2024 (2 weeks ago) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 9 July 2024 (2 weeks ago) • Edgar (US Regulatory)

Health Canada Authorizes RYBREVANT® (amivantamab) in Combination with Carboplatin and Pemetrexed as the Only Targeted First-line Treatment Approved for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Wednesday 3 July 2024 (3 weeks ago) • PR Newswire (Canada)

More Johnson and Johnson News Articles

Tissages Bruggeman

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions